About Calibrium
Calibrium is a Healthcare company based in Zurich (Switzerland) founded in 2006 by Richard DiMarchi and Fritz French, and was acquired by Novo Nordisk in August 2015. It operates as a peptide therapies for diabetes and metabolic diseases are developed. Calibrium has raised $1.7 million across 1 funding round from investors including Novo Nordisk, Frazier Healthcare Partners and 5AM Ventures. Its chief executive is Fritz French. Its focus areas include Life Sciences, Diabetes and Drugs. Its competitors include Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Calibrium was founded in 2006 and is based in Zurich, Switzerland. Focus is placed on the discovery and early development of peptide-based therapies targeting diabetes and related metabolic diseases. Operations center on advancing these treatments through preclinical stages within the biotechnology sector. Leadership includes co-founders Richard DiMarchi and Fritz French, with Bernd Kammerlander serving as CEO.
- Headquarters Zurich, Switzerland
- Founders Richard DiMarchi, Fritz French
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website calibrium.com
- Social LinkedIn
- Acquired by Novo Nordisk (Aug 2015)
- Total Equity Funding$1.7M (USD)
in 1 rounds
- Latest Funding Round$1.7M (USD), Seed
Dec 2013
- InvestorsNovo Nordisk
& 3 more
- Acquired byNovo Nordisk
(Aug 2015)
Funding Insights of Calibrium
Calibrium has successfully raised a total of $1.7M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.7 million completed in December 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.7M
- Total Rounds 1
- Last Round Seed — $1.7M
- First Round $1.7M
(Dec 2013)
- Investors Count 3
All 1 funding rounds of Calibrium with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2013 | $1.7M | Seed | – | Frazier Healthcare Partners, 5AM Ventures |
4 investors in total: 4 institutional.
Investors in Calibrium
Calibrium has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Novo Nordisk, Frazier Healthcare Partners and 5AM Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Venture capital fund backed incubator focused on the healthcare startups | – | 5amventures.com | San Francisco, United States | |
BioCrossroads is focused on advancing Indiana's life sciences industry. | – | biocrossroads.com | Indianapolis, United States | |
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. | 1923 | novonordisk.com | Bagsvaerd, Denmark |
Investor details for Calibrium
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Calibrium
3 people are tracked at Calibrium (3 in leadership).
| Name | Role | Group |
|---|---|---|
Richard DiMarchi | Co-Founder | Leadership |
Fritz French | Co-Founder & ex-CEO | Leadership |
Bernd Kammerlander | CEO | Leadership |
Complete people profiles for Calibrium
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Calibrium
3 dated milestones of Calibrium across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Calibrium is founded.
- Funding First funding round of $1.7M.
- Exit Acquired by Novo Nordisk.
Competitors of Calibrium
Calibrium has 9 listed competitors in our database, 8 of them funded. They include Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| adocia.com | 2005 | Lyon, France | $26M | – | Therapeutics for diabetes and obesity treatment are developed. | |
| pendulumlife.com | 2012 | San Francisco, United States | $109.5M | 55 | Pendulum is focused on developing advanced probiotic solutions. | |
| rezolutebio.com | 2012 | Denver, United States | – | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | |
| viacyte.com | 1999 | San Diego, United States | $389.03M | 126 | Cell therapy for diabetes is developed from stem cells. | |
| huamedicine.com | 2011 | Shanghai, China | $125M | – | Glucokinase activators for type-2 diabetes treatment are developed. |
Detailed competitors of Calibrium
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
10 companies that operate in the same segment as Calibrium (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 237 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Calibrium
Calibrium was founded in 2006 and raised its 1st funding round 7 years after it was founded.
Calibrium is headquartered in Zurich, Switzerland.
Fritz French is the current CEO of Calibrium. They have also founded this company.
Calibrium is a funded company, having raised a total of $1.7M across 1 funding round to date. The company's 1st funding round was a Seed of $1.7M, raised on Dec 2013.
Calibrium was founded in 2006 and is based in Zurich, Switzerland. Focus is placed on the discovery and early development of peptide-based therapies targeting diabetes and related metabolic diseases. Operations center on advancing these treatments through preclinical stages within the biotechnology sector. Leadership includes co-founders Richard DiMarchi and Fritz French, with Bernd Kammerlander serving as CEO.
Calibrium's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Calibrium has 4 investors. Key investors include Novo Nordisk, Frazier Healthcare Partners, 5AM Ventures, and BioCrossroads.
Yes. Calibrium was acquired by Novo Nordisk in August 2015.